ASND | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 3%

Liquidity 50%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.63%

1 Month

12.12%

3 Months

12.84%

6 Months

21.88%

1 Year

51.71%

2 Year

72.05%

Key data

Stock price

$244.48

P/E Ratio

0.00

DAY RANGE

$241.64 - $245.57

EPS

-$5.07

52 WEEK RANGE

$150.89 - $250.74

52 WEEK CHANGE

$53.64

MARKET CAP

7.945 B

YIELD

N/A

SHARES OUTSTANDING

58.231 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

09-02-2025

BETA

0.88

PUBLIC FLOAT

AVERAGE 10 VOLUME

$636,154

AVERAGE 30 VOLUME

$545,792

Company detail

CEO: Jan M. Mikkelsen
Region: US
Website: ascendispharma.com
Employees: 640
IPO year: 2008

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

SKYTROFA for treating patients with growth hormone deficiency (GHD) Ascendis Pharma A/S focuses on developing therapeutics for unmet medical needs. It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD. TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

ASND - Ascendis Pharma A/S